Lymphoma

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large B-cell lymphoma.

Cancer runs in the family, and after I’d dealt with two breast cancers, my brother came down with lymphoma.

Years after losing my brother to Hodgkin’s lymphoma, I learned something about how he felt facing a terminal diagnosis by studying an old Polaroid.

Nutrition is a challenge for many patients with cancer.

Cancer is one of the most expensive medical conditions to treat in the U.S.

Brukinsa plus R-CHOP demonstrated high efficacy and durable responses in double-expressor lymphoma, with manageable safety, supporting further phase 3 trials.

Replacing transplant and chemo with CI-based therapy and ISRT maintains survival, reduces side effects in younger patients with classic Hodgkin lymphoma.

Treatment with the CAR T-cell therapy cema-cel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphoma.

A year ago, I was told my lymphoma had worsened, but a miraculous turn of events spared me from aggressive chemotherapy, making me grateful for each day of life.

Odronextamab demonstrated a manageable safety profile and generated durable responses in patients with R/R DLBCL who have progressed after CAR-T therapy.

The myth that "healthy people don’t get cancer" contributed to my shame, but I’ve learned that cancer can affect anyone, regardless of lifestyle choices.

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been discontinued.

The FDA has approved Adcetris plus Revlimid and Rituxan in adults with relapsed or refractory large B-cell lymphoma.

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL.

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s this week’s cancer news.

Dr. Christopher Flowers discusses MRD testing in cancer care, why this is an important concept to understand and how it relates to recurrence in patients.

Patients with lymphoma or leukemia with methotrexate-induced acute kidney injury experienced improved renal outcomes following glucarpidase treatment.

Dr. Christopher R. Flowers delved into the meaning of MRD, discussing different ways that it may be tested for in patients with various types of cancer.

Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic malignancies.

Despite being declared cancer-free after initial treatment, I grapple with survivor's guilt, questioning why my lymphoma responded to therapy while others did not.

Throughout the year, CURE® contributors shared personal stories and reflections highlighting the multifaceted nature of cancer care.

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory follicular lymphoma.

After sharing his cancer story online, Jace Yawnick is in a state of technical remission after receiving a diagnosis of non-Hodgkin lymphoma at age 25.

The real-world effectiveness of Monjuvi for relapsed or refractory diffuse large B-cell lymphoma in the U.S. was demonstrated, according to data from a retrospective analysis.

Watching "Scrooge" every Christmas made me reflect on my own journey, where my past struggles with illness taught me valuable lessons about forgiveness, love and joy.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

When you’ve had cancer do doctors assume every ailment is cancer for you?

Patients with advanced Hodgkin lymphoma demonstrated significantly improved survival benefits with an Opdivo regimen versus an Adcetris regimen.

As a four-time cancer survivor, I can tell you that survivorship means many things to each survivor.